Patents by Inventor Merle Olson

Merle Olson has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11964046
    Abstract: The present invention is a topical composition for the treatment of animals, particularly animals in pain, wherein the composition comprises an effective amount of a local anesthetic (e.g., lidocaine) and an analgesic (e.g., meloxicam).
    Type: Grant
    Filed: May 17, 2017
    Date of Patent: April 23, 2024
    Assignee: ALBERTA VETERINARY LABORATORIES LTD
    Inventor: Merle Olson
  • Publication number: 20230014993
    Abstract: Disclosed are bolus compositions for ruminants comprising potassium phosphate dibasic and water configured to rapidly dissolve in the rumen for use in the prevention or treatment of hypokalemia and hypophosphatemia. These conditions occur in ruminants at around the time of calving or during periods when ruminants do not eat (anorexia). The bolus compositions may comprise a coating that is compatible with a ruminant digestive tract. Additionally, the bolus compositions may comprise a wick which may be used during the manufacturing process to facilitate the bulk handling and transfer of the bolus compositions.
    Type: Application
    Filed: December 11, 2020
    Publication date: January 19, 2023
    Inventor: Merle OLSON
  • Publication number: 20230000800
    Abstract: Disclosed are bolus compositions for use in the treatment or prevention of hypocalcemia and choline deficiency in ruminants. The bolus compositions may comprise rumen-protected choline, one or more calcium salts, and water.
    Type: Application
    Filed: December 11, 2020
    Publication date: January 5, 2023
    Inventor: Merle OLSON
  • Publication number: 20210007903
    Abstract: Disclosed is a deformable analgesic nose plug, comprising a deformable core material and an outer coating provided on said deformable core material, wherein said outer coating comprises one or more analgesic compounds. The nose plug has a tapered distal end for insertion into a nostril and a proximal end whereby the nose plug is inserted into the nostril. The deformable core material may comprise a multi-phasic core material wherein a first phase of the multi-phasic core material is a solid or a semi-solid structure at a temperature of 35° C. or less and a second phase of the multi-phasic core material is characterized by liquefaction at a temperature of 37° C. or greater. The deformable core material may also comprise a porous resiliently compressible substrate. The deformable porous resiliently compressible core material may be one of polymeric sponges, naturally occurring sponges, fluffy cellulosic materials, cotton, rolled gauze, and mixtures thereof.
    Type: Application
    Filed: September 24, 2020
    Publication date: January 14, 2021
    Applicant: Rhinoclear Nasal Care Solutions Inc.
    Inventors: Bradford Mechor, Merle Olson
  • Publication number: 20190314271
    Abstract: The present invention is a topical composition for the treatment of animals, particularly animals in pain, wherein the composition comprises an effective amount of a local anesthetic (e.g., lidocaine) and an analgesic (e.g., meloxicam).
    Type: Application
    Filed: May 17, 2017
    Publication date: October 17, 2019
    Inventor: Merle Olson
  • Publication number: 20190254961
    Abstract: A deformable nose plug, comprising a deformable core material and an outer coating provided on said deformable core material, wherein said said outer coating comprises a hemostatic compound. The nose plug has a tapered distal end for insertion into a nostril and a proximal end whereby the nose plug is inserted into the nostril. The deformable core material may comprise a multi-phasic core material wherein a first phase of the multi-phasic core material is characterized by a solid or a semi-solid structure at a temperature of 35° C. or less, and wherein a second phase of the multi-phasic core material is characterized by liquifaction at a temperature of 37° C. or greater. Alternatively, the deformable core material may comprise a porous resiliently compressible substrate. Alternatively, the deformable porous resiliently compressible core material may be one of polymeric sponges, naturally occurring sponges, fluffy cellulosic materials, cotton, rolled gauze, and mixtures thereof.
    Type: Application
    Filed: October 27, 2017
    Publication date: August 22, 2019
    Applicant: Rhinoclear Nasal Care Solutions Inc.
    Inventors: Bradford Mechor, Merle Olson
  • Publication number: 20080075730
    Abstract: This disclosure relates to methods and compositions to regulate biofilm formation. In particular, the disclosure provides methods and compositions that relate to regulation of biofilm formation by modulating the GacA/GacS regulatory system as well as methods and compositions for inhibiting small colony variant formation and reversion of resistant bacteria to a wild-type phenotype.
    Type: Application
    Filed: January 12, 2007
    Publication date: March 27, 2008
    Applicant: University Technologies International Inc.
    Inventors: Douglas Storey, Michael Parkins, Howard Ceri, James Davies, Merle Olson, Lyriam Marques
  • Publication number: 20060166358
    Abstract: Biofilm forming organisms are incubated to form a biofilm on projections by providing a flow of liquid growth medium across projections, the direction of the flow of liquid being repeatedly changed, and an assay made of the resulting biofilm. Biofilm forming organisms are incubated to form a biofilm on projections arranged in rows, with several projections in each row, while providing a flow of liquid growth medium across each row of projections, and an assay made of the resulting biofilm. Sensitivity of the biofilm to antimicrobial reagent may be determined by treating the projections with antimicrobial reagent before carrying out the assay, by treating each row of projections with a different antimicrobial reagent, and each of the projections in a row with a different concentration of antimicrobial reagent.
    Type: Application
    Filed: December 15, 2005
    Publication date: July 27, 2006
    Applicant: University Technologies International, Inc.
    Inventors: Howard Ceri, Merle Olson, Douglas Morck, Ronald Read, Andre Buret
  • Publication number: 20060014684
    Abstract: This invention relates to treating or preventing pathogenic infections with an epidermal growth factor (EGF). EGF is capable of inhibiting pathogenic colonization of pathogens in a variety of tissue or cell types. Since pathogenic colonization is essential for pathogenic infection, EGF can be used as an effective preventive and therapeutic agent for pathogenic infections, particularly in the urogenital tract. A method of increasing weight gain in an animal by administering epidermal growth factor is also described.
    Type: Application
    Filed: December 10, 2004
    Publication date: January 19, 2006
    Applicant: University Technologies International Inc.
    Inventors: Andre Buret, D. Gall, Merle Olson, James Hardin